AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 1 - (NewsRx.com & NewsRx.net) -- Pfizer Inc said that results from clinical studies investigating the use of Viagra (sildenafil citrate) as a treatment for female sexual arousal disorder (FSAD) do not support a regulatory filing.
Pfizer began its FSAD research program in 1996. To date the company has conducted several large-scale placebo-controlled studies involving approximately 3,000 women. While Viagra was found to be safe in all studies, efficacy data were inconclusive. Pfizer said the program would draw to a close this month.
A highly prevalent condition with a major impact on quality of life, FSAD is a complex constellation of symptoms that are difficult to identify, measure and treat. The American Foundation for Urological Diseases defines FSAD as a persistent inability to attain or maintain sufficient sexual excitement that causes personal distress.
The condition, which may occur alone or in conjunction with other female sexual disorders, is believed to result from a broad range of medical and psychological conditions.
"FSAD is an emerging area of research and is far more complex than male erectile dysfunction," said Dr. Joe Feczko, president of worldwide development at Pfizer. "Diagnosing FSAD involves assessing physical, emotional, and relationship factors, and these complex and interdependent factors make measuring a medicine's effect very difficult."
Pfizer discovered and over the next ...
Source: HighBeam Research, Viagra clinical studies in women do not support regulatory filing.